Comparison of a Solid Phase Human- versus Porcine- Thyrotropin Receptor-based Immunoassay for the Measurement of Thyrotropin Receptor Antibodies in Patients with Thyroid Diseases

Abstract

Thyrotropin receptor (TSHR) antibody (TRAb) assays based on human or porcine TSHR which are coated to a solid phase are the most commonly used detection methods in clinical practice for patients with thyroid diseases. Yet the difference of the diagnostic values of the two TRAb assays is largely unclear. The aim of our present study was to evaluate the clinical perfomance of a solid phase porcine TRAb assay based on an ELISA technique (TRAb-porcine) and a human TRAb assay based on a chemiluminescence signal detection procedure (TRAb-human). Of 158 patients enrolled in the study, 84 suffered from Graves’ disease (GD), 34 had Hashimoto's thyroiditis (HT) and 40 had euthyroid nodular thyroid disease (NTD) without signs of autoimmunity. TRAb measurements were performed according to the manufacturer's instructions. The mean values of TRAb titers detected by the TRAb-human and TRAb-porcine assays in patients with GD were 12.14±10.80 IU/L and 15.27±13.65 IU/L, respectively. TRAb were detected in 80 and 78 out of 84 GD patients by the TRAb-human and TRAb-porcine assay, respectively. The diagnostic sensitivity of the TRAb-human and TRAb-porcine immunoassay was 95.2 and 92.9% respectively, by 100% specificity of both methods. TRAb values in GD patients detected by the TRAb-human and TRAb-porcine assays were significantly correlated (r=0.929, p<0.0001). Our results indicate that the second generation TRAb-porcine assay based on solid phase technology had a slightly lower diagnostic sensitivity compared to the TRAb-human assay.

Key words

thyrotropin receptor antibody - second generation TRAb assay - Graves’ disease - ELISA

References

• 1 Weetman AP. Cellular immune responses in autoimmune thyroid disease.  Clin Endocrinol. 2004;  61 405-413
• 2 Guarneri F, Benvenga S. Environmental factors and genetic background that interact to cause autoimmune thyroid disease.  Cur Opin Endocrinol Diab Obes. 2007;  14 398-409
• 3 Rapoport B, MacLachlan SM. The thyrotropin receptor in Graves’ disease.  Thyroid. 2007;  17 911-922
• 4 Rees Smith B, Sanders J, Furmaniak J. TSH receptor antibodies.  Thyroid. 2007;  17 928-938
• 5 Schott M, Scherbaum WA, Morgenthaler NG. Thyrotropin receptor autoantibodies in Graves’ disease.  Trends Endocrinol Metab. 2005;  16 243-248
• 6 Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves’ disease and multinodular toxic goitre: a comparison of two competitive binding assays.  Clin Endocrinol (Oxf). 2001;  55 ((3)) 381-390
• 7 Paunkovic N, Paunkovic J. The diagnostic criteria of Graves’ disease and especially the thyrotropin receptor antibody: our own experience.  Hell J Nucl Med. 2007;  10 89-94
• 8 Izumi Y, Takeoka K, Amino N. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiated relapse of Graves’ thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves’ disease.  Endocr J. 2005;  52 493-497
• 9 Eckstein AK, Plicht M, Lax H, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease.  J Clin Endocrinol Metab. 2006;  91 3464-3470
• 10 Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves’ hyperthyroidism.  Eur J Endocrinol. 2005;  153 489-498
• 11 Schott M, Feldkamp J, Bathan C, Fritzen R, Scherbaum WA, Seissler J. Detecting TSH-receptor antibodies with the recombinant TBII assay: technical and clinical evaluation.  Horm Metab Res. 2000;  32 ((10)) 429-435
• 12 Carella C, Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Nersita R, Iorio S, Amato G, Braverman LE, Roti E. Serum thyrotropin receptor antibodies concentrations in patients with Graves’ disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.  Thyroid. 2006;  16 295-302
• 13 Schott M, Morgenthaler NG, Fritzen R, Feldkamp J, Willenberg HS, Scherbaum WA, Seiissler J. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves’ disease.  Horm Metab Res. 2004;  36 92-96
• 14 Hoermann R, Quadbeck B, Roggenbuck U, Szabolcs I, Pfeilschifter J, Meng W, Reschke K, Hackenberg K, Dettmann J, Prehn B, Hirche H, Mann K. Relapse of Graves’ disease after successful outcome of antithyroid drug therapy: Results of a prospective randomized study on the use of levothyroxine.  Thyroid. 2002;  12 1119-1128
• 15 Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, Pirola I, Martino ED, Rosei EA. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves’ disease: a 120 months prospective study.  Endocr J. 2007;  54 ((5)) 713-720
• 16 Schott M, Eckstein A, Willenberg HS, Nguyen T-B-T, Morgenthaler NG, Scherbaum WA. Improved prediction of relapse of Graves’ thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies.  Horm Metab Res. 2007;  39 56-61
• 17 Morgenthaler NG. New assay systems for thyroid receptor antibodies.  Current Opin Endocrinol Diabetes. 1999;  6 251-260
• 18 Zoephel K, Wunderlich G. Predictive value of TSH receprot antibody measurement in Graves’ disease is independent on the TSH receptor (human or porcine) but depends on the generation of the assay used.  Endocr J. 2006;  53 869-870
• 19 Okamoto Y, Tanigawa SI, Ishikawa K, Hamada N. Ths receptor antibody measurements and prediction of remission in Graves’ disease patients treated with minimum maintenance doses of antithyroid drugs.  Endocr J. 2006;  53 467-472
• 20 Cardia MS, Lima N, Knobel M, Medeiros-Neto G. Evaluvation of a coated-tube assay for antithyrotropin receptor antibodies in patients with Graves’ disease and other thyroid disorders.  Thyroid. 2004;  14 295-300
• 21 Feldt-Rasmussen U, Schleusner H, Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long-term remission after medical therapy of Graves’ disease.  J Clin Endocrinol Metab. 1994;  78 98-102
• 22 Costagliola S, Morgenthaler NG, Hoermann R, Badenhoop K, Struck J, Freitag D, Poertl S, Weglohner W, Hollidt JM, Quadbeck B, Dumont JE, Schumm-Draeger P-M, Bergmann A, Mann K, Vassart G, Usadel K-H. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves’ disease.  J Clin Endocrinol Metab. 1999;  84 90-97
• 23 Kamijo K. TSH-receptor antibody measurement in patients with various thyrotoxicosis and Hashimoto's thyroiditis: a comparison of two two-step assays, coated plate ELISA using porcine TSH-receptor and coated tube radioassay using human recombinant TSH-receptor.  Endocr J. 2003;  50 ((1)) 113-116
• 24 Rees Smith B, Bolton J, Young S, Collyer A, Weeden A, Bradburg J, Weightman D, Perros P, Sanders J, Furmaniak J. A new assay for thyrotropin receptor autoantibodies.  Thyroid. 2004;  14 830-835
• 25 Abalovich M, Amino N, Barbour LA, Cobin RH, Groot LJ, Glinoer D, Mandel SJ, Stagnaro-Green Al. Management of thyroid dysfunction during pregnancy and postpartum: an endocrine society clinical practice guideline.  J Clin Endocrinol Metab. 2007;  92 S1-S47
• 26 Luton D, Le Gac I, Vuillard E, Castanet M, Guibourdenche J, Noel M, Toubert ME, Léger J, Boissinot C, Schlageter MH, Garel C, Tébeka B, Oury JF, Czernichow P, Polak M. Management of Graves’ disease during pregnancy: the key role of fetal thyroid gland monitoring.  J Clin Endocrinol Metab. 2005;  90 ((11)) 6093-6098
• 27 Chan GW, Mandel SJ. Therapy insight: management of Graves’ disease during pregnancy.  Nat Clin Pract Endocrinol Metab. 2007;  3 ((6)) 470-478
• 28 Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves’ disease.  Thyroid. 2005;  15 ((9)) 1047-1054

1 Both authors contributed equally

Correspondence